Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00837876 · ClinicalTrials.gov registry record · Phase 2
Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
A Phase 2 study of Pancreatic Cancer, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
- 6
- Study locations
NCT00837876: Completed Phase 2 study of Pancreatic Cancer, sponsored by Vanderbilt-Ingram Cancer Center.
NCT00837876 is a Phase 2 study of Pancreatic Cancer that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 37 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (91% lower). The trial reports 6 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00837876, a Phase 2 study of Pancreatic Cancer, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
- 6
- Study locations
Study Summary
RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving sorafenib together with erlotinib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving sorafenib together with erlotinib works in treating patients with pancreatic cancer that cannot be removed by surgery.
Primary Outcome
Number of patients with progression-free survival at 8 weeks
Conditions Studied
Interventions
- DRUG Sorafenib
- DRUG Erlotinb
Study Locations (6)
Tennessee
- Erlanger Cancer Center at Erlanger Hospital - Baroness - Chattanooga
- Baptist Regional Cancer Center at Baptist Riverside - Knoxville
- Vanderbilt-Ingram Cancer Center - Cool Springs - Nashville
- Vanderbilt-Ingram Cancer Center at Franklin - Nashville
- Vanderbilt-Ingram Cancer Center - Nashville
Kentucky
- Purchase Cancer Group - Paducah - Paducah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2008-10 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
What the finished NCT00837876 record still lists
NCT00837876 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Sorafenib is the first listed.
NCT00837876 lists 6 locations in 2 states (Tennessee, Kentucky).
Frequently Asked Questions
What is clinical trial NCT00837876 about?
NCT00837876 is a clinical study titled "Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery". RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving sorafenib together with erlotinib may kill more tumor cells. PURPOSE: This phas...
What is the current status of trial NCT00837876?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2008-10. Estimated completion is 2012-11.
What conditions does trial NCT00837876 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT00837876?
The interventions under investigation include: Sorafenib (DRUG), Erlotinb (DRUG).
Who is sponsoring clinical trial NCT00837876?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00837876 being conducted?
This trial has 6 study locations across Kentucky, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00837876's enrollment target sits among peer trials
37 177th of 278 higher than 101 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia